STRO / Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial cancer more_horizontal

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares t more_horizontal

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares t more_horizontal

Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti more_horizontal

STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the mole more_horizontal

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the n more_horizontal

Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revis more_horizontal